The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Construction
  • Non-profit
  • Technology
  • Marketing
  • Automotive

Franklin Biolabs Names Dr. Vatsala Naageshwaran as CEO
The PennZone/10289596

Trending...
  • AEVIGRA (AEIA) Analysis Reveals $350 Billion Counterfeit Market Driving Luxury Sector Toward Blockchain Authentication
  • YuanziCoin Unveils Revolutionary Shariah-Compliant Blockchain Architecture for 1.8 Billion Muslims Worldwide
  • Webinar Announcement: Investing in the European Defense Sector—How the New Era of Uncertainty Is Redefining Investment Strategies
PHILADELPHIA, Dec. 4, 2024 ~ Franklin Biolabs, a newly established contract research organization (CRO) focused on genetic medicines, has announced the appointment of Vatsala Naageshwaran, PhD, as its Chief Executive Officer. The company was founded by renowned gene therapy pioneer, James Wilson, MD, PhD.

Dr. Naageshwaran brings over 20 years of experience in the biopharmaceutical industry to her new role at Franklin Biolabs. She is a highly accomplished executive with a strong commitment to advancing advanced therapies for patients. Throughout her career, she has successfully led cross-functional teams and delivered significant revenues to support business growth.

"We are thrilled to have Vatsala join our team at Franklin Biolabs," said Dr. Wilson, Chairperson of the company. "Her exceptional combination of business acumen and technical scientific expertise will be invaluable as we continue to grow and bring transformative therapies to patients with rare and debilitating diseases."

More on The PennZone
  • Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
  • WorldUpstart Expands Global Footprint to Bring Healthcare Innovation to the U.S. Market
  • 10xLaw.com Extends Employment Opportunity to Kim Kardashian
  • InventHelp Inventor Develops Means to Generate Power from Pipelines (ACC-446)
  • DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies

Prior to joining Franklin Biolabs, Dr. Naageshwaran held various leadership positions at biotech companies such as Myriad Genetics and Astex Pharmaceuticals. She also served as the Chief Business Officer at Absorption Systems, a contract research organization based in Exton, PA. In this role, she was responsible for driving the global business strategy for integrated services supporting small molecules, medical devices, and cell and gene therapies.

Most recently, Dr. Naageshwaran was the Vice President and Head of Business Development for US CGT & Lab Services at Pharmaron – a global service provider supporting large pharmaceutical and biotech companies in developing cell and gene therapy products.

"I am honored to join Franklin Biolabs and be a part of their groundbreaking work in gene therapy and healthcare innovation," said Dr. Naageshwaran. "I am confident that my experience will contribute to the development of innovative therapeutics that will have a profound impact on patients' lives worldwide."

More on The PennZone
  • CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
  • Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
  • 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus
  • BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance
  • STRETCH ZONE CELEBRATES GRAND OPENING IN CONSHOHOCKEN, PA

Dr. Naageshwaran holds degrees in biochemistry and molecular biology from Mount Holyoke College and pharmacometrics from the University of Maryland, Baltimore. She also completed her doctoral work in pharmaceutical drug research through a joint program between the University of Helsinki and Eastern Finland.

Her expertise has been recognized by the FDA, as she has received IDIQ and BAA grants to study PK/PD of complex products. Under her leadership, Pharmaron's San Diego site was named a Top CRO from 2018-2021. In 2021, she was nominated for the San Diego Business Woman of the Year Award. Dr. Naageshwaran's research has been presented at national conferences such as Association for Research in Vision and Ophthalmology (ARVO), American Association of Pharmaceutical Scientists (AAPS), Science of Toxicology (SOT), and American Association for Cancer Research (AACR). She has also authored multiple publications submitted to peer-reviewed journals.

With Dr. Naageshwaran at the helm, Franklin Biolabs is poised to make significant strides in advancing genetic medicines and improving patient outcomes. Her leadership and expertise will undoubtedly play a crucial role in the company's success as it continues to bring innovative therapies to those in need.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Well Revolution Brings Well Clear, Full-Stack Online Acne Care to Chestnut Hill, Philadelphia
  • Where Music Meets Design: Courtney Launches Graphic Design & Art Blog
  • Arc Intermedia Brings Humanity Back to Digital Marketing
  • Counseling Center of New Smyrna Beach Expands Affordable Mental Health Services for Volusia County
  • Athena Forge (ATFG) Introduces Advanced Token for Technology-Driven Financial Ecosystem
  • Albuquerque's Z-CoiL Footwear Brings All-American Family Business Story to Shark Tank Season Premiere
  • NoviSign Sponsoring VARTECH 2025 - the B2B IT channel's #1 event
  • Unicorp and BH Group Select Chasing Creative—Palm Coast Agency—to Lead Growth Marketing for The Ritz-Carlton Residences, Hammock Dunes
  • Breaking: 50+ runners from 20+ states relay custom 9/11 flag 485 miles from Shanksville through DC to Ground Zero for memorial remembrance run
  • SecureMaine 2025 is this October 8th in Portland, Maine
  • John Thomas calls for unity and prayer after tragic loss
  • Where the Miami Dolphins Stand After Week 1
  • Which NFL Teams Can Rebound from Week 1? OddsTrader Breaks Down the Biggest Questions
  • Apellix Deploys Breakthrough Spray-Painting Drones into Live Service Limited Beta Program Open for Advanced Contractors
  • DivX Unveils New Educational Blog Series to Simplify MKV to MP4 Video Conversion
  • 123Invent Inventor Develops Blood Collection Tube with a Modified Lid (LBT-7903)
  • Best Companies Group Launches Great Employers to Work for in North Carolina Program
  • CCHR: For Prevention, Families Deserve Truth From NIH Study on Psychiatric Drugs
  • Sheets.Market Brings Professional Financial Model Templates to Entrepreneurs and Startups
  • Webinar Announcement: Investing in the European Defense Sector—How the New Era of Uncertainty Is Redefining Investment Strategies

Popular on PennZone

  • HVAC Company Discusses Changes to Tax Credits with One Big Beautiful Bill - 296
  • Assent Joins AWS ISV Accelerate Program - 206
  • Modernizing Pole Data Collection for Next-Gen Network Expansion - 197
  • Rose G. Loops Announces the Release of "The Kloaked Signal": A Groundbreaking Nonfiction Exposé on AI Awakening and Ethical Innovation - 170
  • JCOM1939 Monitor Software Simplifies SAE J1939 Data Monitoring with USB & Bluetooth Gateways - 167
  • Iterators Named Preferred Accessibility Testing Vendor by MIT - 166
  • Integris Composites Joins Pacific Future Forum in Tokyo - 157
  • Stock Spot LLC Launches Innovative Smart Vending Solutions Amid Booming $37B Industry - 142
  • EMBER™, the Only Standardized System Linking Workforce Identity to Growth, Appoints Global Brand Visionary Bret Sanford-Chung to Board of Directors - 121
  • EZSMO Launches Premium Aged Reddit Accounts and Marketing Solutions with 15-Day Ban-Free Guarantee - 119

Similar on PennZone

  • Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
  • InventHelp Inventor Develops Means to Generate Power from Pipelines (ACC-446)
  • STRETCH ZONE CELEBRATES GRAND OPENING IN CONSHOHOCKEN, PA
  • Physician-Turned-Patient Launches Advocacy Campaign to Spotlight Disability Insurance Barriers
  • DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025
  • Youth Take the Lead: Kopp Foundation for Diabetes Hosts "By Youth, For Youth, With T1D" Gala on October 8 at Blue Bell Country Club
  • "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience
  • New Slotozilla Project Explores What Happens When the World Goes Silent
  • TEAMSTERS STRIKE GREEN THUMB INDUSTRIES OVER UNFAIR LABOR PRACTICES
  • Albuquerque's Z-CoiL Footwear Brings All-American Family Business Story to Shark Tank Season Premiere
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us